AstraZeneca Plc’s experimental breast cancer pill delayed disease progression by over six months, according to data from a new study that is likely to capture investors’ attention.Camizestrant, in combination with other cancer medicines,

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing,

AstraZenecas experimental pill camizestrant significantly reduced the risk of disease progression or death in hormone receptor-positive, HER2-negative breast cancer, according to new data presented at the American